The British Association of CFS/ME (BACME,
of which Dr Esther Crawley is Chair) supports the current
NICE Guideline CG53 and its recommendation of only cognitive
behavioural therapy and graded exercise in the management of
ME/CFS. BACME has taken on the role of training NHS staff
accordingly, even though it seems to be accountable only to
itself; it is to hold a meeting on 13th-14th
October 2010 at Milton Keynes and its provisional programme
affirms that Professor Peter White (Chief Investigator of
the MRC PACE Trial on ME/CFS) will speak about it in a talk
entitled “PACE trial: so near yet so far”. The
BACME notice goes on to say that if the PACE Trial outcome
results are not published by then, Professor White will
present the design, progress and baseline data from the
trial.
From over 2,000 pages of information
obtained under the Freedom of Information Act, much is already
known about the design and progress of the PACE Trial (click
here),
including the fact that its entry criteria were intentionally
broad (“We chose these broad criteria in order to enhance
generalisability and recruitment”; Trial Identifier 3.6).
Despite the use of such broad entry criteria, there were serious
recruitment difficulties, so the entry criteria were broadened
even further when on 14th July 2006 Peter White
sought approval from the West Midlands MREC to write to GPs
imploring them to send anyone with “chronic fatigue (or
synonym)” for entry into the PACE Trial, thereby opening the
trial to anyone who was merely chronically tired.
Given the customary requirement for study
cohorts to be as homogeneous as possibly, this seems to defy
logic: how can the Wessely School’s long-held desire to
“clarify the role that psychiatric disorders have in fatiguing
illness” (Ann Int Med 1994:121:12:953-959) and their
inclusion of persons with psychiatric disorders possibly restore
to health people with the neuroimmune disease ME/CFS who are
allegedly the subjects under study, any more than it would be
able to restore to health people with multiple sclerosis or
motor neurone disease?
The fundamental point is that the PACE
Trial interventions are not designed to offer psychological
support to those coping with life-shattering disease, but to
comprehensively disabuse them of their belief that they suffer
from a serious organic disease. If the aim of the PACE Trial is
merely to indulge the Wessely School psychiatrists’ unproven
beliefs (which Professor Michael Sharpe has already admitted are
“without theoretical foundation” (click
here), on what grounds did it gain ethical approval?
How can the results of a trial that was
deliberately designed to conflate people with behavioural
disorders, idiopathic fatigue, fibromyalgia and people with
ME/CFS (characterised by immunological, neurological, metabolic,
cardiovascular, respiratory and musculo-skeletal dysfunction,
the cardinal symptom being post-exertional exhaustion
accompanied by malaise) be equally applicable to and effective
for such diverse disorders?
If the role of psychiatric morbidity in “fatiguing
illness” is being studied, then why was the trial designed
to exclude people with multiple sclerosis who definitely
experience profound and disabling fatigue?
The answer, of course, is that the PACE
Trial limits the study to those people suffering from disorders
that the Wessely School deem to be “mental” disorders.
Notably, in an exchange of correspondence
(Conversing with Professor Simon Wessely: (
http://livingwithchronicfatiguesyndrome.wordpress.com/2010/08/29/conversing-with-professor-simon-wessely-part2/),
Wessely states:
“…it is essential in any study to make it
clear exactly where your subjects come from – without that it is
impossible to generalise from any report/paper/treatment. This
not a new observation – you will see that we pointed that out in
1996, and have continued in all papers to make that distinction
abundantly clear”. |
Many would challenge Wessely’s assertion
that his study cohorts have always been strictly defined;
moreover, is it not curious, given that he is in charge of the
Clinical Trials Unit for the PACE Trial, that Wessely apparently
saw no need to exercise such care in the PACE cohort? Does this
not mean that, on Wessely’s own admission, if a cohort is
heterogeneous (which the PACE Trial undoubtedly is), then the
conclusions cannot be generalised and so will have no clinical
relevance and thus be a waste of tax-payers’ money?
It has already been shown that the PACE
Trial Investigators apparently did not adhere to good research
practice on numerous other counts also, including their apparent
failure to observe either the AGREE Instrument or the
Declaration of Helsinki, and there are consequential concerns
about how meticulously they will adhere to the CONSORT
Statement. CONSORT (Consolidated Standards of Reporting Trials)
was developed by a group of scientists and editors in 1996; it
was updated in 2001 and again in 2010 and it consists of a
checklist that authors are recommended to use for reporting a
randomised controlled trial (RCT).
It is based on the premise
that “The whole of medicine depends on the transparent
reporting of clinical trials” and its authors note that
trials with inadequate methods are associated with bias,
especially exaggerated treatment effects, and that reporting is
not only often incomplete but also sometimes inaccurate. They
point out that:
“Biased results from poorly designed and
reported trials can mislead decision making in health care at
all levels, from treatment decisions for a patient to
formulation of national public health policies….Bias jeopardises
even RCTs, however, if investigators carry out such trials
improperly…The methods used should be complete and transparent
so that readers can readily differentiate trials with unbiased
results from those with questionable results….We encourage peer
reviewers and editors to use the CONSORT checklist to assess
whether authors have reported on these items”
(D Moher / D.
Altman et al; BMJ 2010:340:c869). |
One of the items on the
CONSORT checklist relates to trial design, with particular
emphasis on important changes to eligibility criteria that are
made after trial commencement (as occurred in the PACE Trial) –
and the reasons for them.
Furthermore, as an experienced member of
a Research Ethics Committee who is familiar with the PACE Trial
documentation has pointed out, the PACE Trial is a classic
example of over-measurement of variables (i.e. it measures too
many variables so it is almost inevitable that the data will
show spurious “positive” results which in fact have no clinical
meaning).
These are very serious matters that, as
Chief Investigator, Professor White will need to address with
total transparency sooner rather than later.
In response to a previous formal
complaint about the PACE Trial made in 2004 by a former MRC
grant-holder, Elizabeth Mitchell, MRC External Communications
Manager, wrote on 15th November 2004 about the PACE
and FINE Trials:
“The design of these trials have been judged
by international and UK peer review to be appropriate for
delivering the trial objectives, including use of the broad
inclusion criteria”. |
This is undoubtedly so, because if a
proposal is sent for peer review to those who hold similar views
to the Investigators, those reviewers will obviously support
it. The real question is – what exactly were the “trial
objectives”? It was already known that the interventions
used in the trial are at best of little help and at worst are
damaging to those with ME/CFS (ie. the alleged target group) and
that the interventions being studied do not reduce either
fatigue or disability in such patients. Was this in reality an
elaborate exercise for the benefit of the DWP and the
medical/permanent health insurance industry?
It is notable that Dr Cathie Sudlow, an
Edinburgh neurologist who collaborates with Professor Michael
Sharpe, wrote in the BMJ (BMJ 2010:340:c1260) about the
discovery of the retrovirus XMRV in relation to ME/CFS in the
Lombardi/Mikovits et al paper that was published in Science on 9th
October 2009:
“The role of reviewers here is crucial…their
contribution should be publicly recognised and valued by
journals and by the scientific community as part of the
scientific record. This can surely only happen if reviewers
are always openly identified and their comments published”
(emphasis added). |
Indeed, but will this apply to the
PACE Trial? Would it expose bias if so?
Given the recent findings of the
“dramatic association” of a family of retroviruses with
ME/CFS that have been published in both Science and PNAS (click
here), on what
logic or evidence do the PACE Trial Principal Investigators
Professors Peter White, Michael Sharpe and Trudie Chalder
continue to rely to support their belief that the Trial will
confirm that “behavioural restructuring” can cure such
seriously sick patients (this is what the Trial manuals claim:
click
here)? If the
PIs do not hold such views, then why have they received £5
million to test those beliefs?
“So near yet so far”: is it the
case that the Wessely School were so near to achieving their
goal of showing that ME/CFS is a somatisation disorder, using
the PACE Trial data, only to be thwarted by the publication of
papers in Science and PNAS showing a strong association of a
retrovirus with ME/CFS, making their goal scientifically
untenable?
Notwithstanding, the way seems to be
being paved by the Wessely School for further disparaging
attacks on those scientists who have found retroviral
involvement in some ME/CFS patients and for yet more dismissal
of the significance of those findings.
Whilst the ground-breaking retroviral
link published in PNAS on 23rd August 2010 was
announced in over 150 outlets world-wide, including Russia and
Latvia, and whilst it was deemed to be of such importance that
it featured on the front page of the Wall Street Journal, the UK
media remained deafeningly silent and there was effectively a
news black-out. It was not until after 31st August
2010 that the Science Media Centre (through which all UK media
announcements about medical/scientific issues must now seemingly
pass, and where Professor Simon Wessely is a member of the
Scientific Advisory Panel) published a statement (apparently
back-dated to 23rd August 2010) that downplayed the
significance of the retroviral association with ME/CFS.
Entitled “Expert reaction to PNAS
study on viral sequences found in blood of chronic fatigue
patients” and quoting two UK virologists (Professors Robin
Weiss and Myra McClure), the SMC press release was dismissive:
Professor Weiss stated:
“It is based on small numbers….Let’s
hope it is not another claim like MMR…which didn’t hold up
(untrue: the UK High Court recently ruled that the MMR vaccine
is not safe, which the UK Government has been forced to concede:
Sunday Times, 29th August 2010), but I am
sceptical of the claim…One should also bear in mind that no less
than 4 negative reports on this topic (failing to find a
retrovirus link) have been published this year from reputable
groups in the UK, the Netherlands and at the Centre for
Communicable Diseases & Prevention in Atlanta, USA” and
Professor McClure stated: “…it is important to realise that
this group have not detected the virus (XMRV) that claimed media
attention after the publication of Lombardi’s paper in Science
last year. They describe murine leukaemia virus (MLV)-related
sequences that are genetically distinct from XMRV….Several other
groups (including Professor McClure’s own group)…have
employed the same experimental protocol, yet have consistently
failed to detect any retrovirus in CFS patients”. |
The SMC has an established track record
of down-playing any association of retroviruses with ME/CFS (for
example,
http://bit.ly/90PAXp and
http://bit.ly/aj27AK ). Given the disparaging tone of the
latest SMC press release, it is little wonder that the UK media
did not bother, even belatedly, to publish anything about it.
It is possible that the SMC’s intention was to ignore the
game-changing discovery entirely, but after it was publicly
asked by a contributor to an internet group
why this important breaking news had not been mentioned
except for a low-key article in the Daily Mail, the SMC perhaps
felt obliged to note it, but did so as dismissively as possible.
Could this be because nothing is to be
allowed to detract from the PACE Trial findings that cognitive
restructuring – including graded aerobic exercise -- are likely
to be claimed to be restorative for patients with ME/CFS?
It is interesting that, over the years,
Professor Wessely has repeatedly asserted that he is no longer
involved with the politics of CFS research, most recently at the
beginning of August 2010 (
http://livingwithchronicfatiguesyndrome.wordpress.com/2010/08/29/conversing-with-professor-simon-wessely-part2/
), yet at the first sign of a significant threat to his
model from the Whittemore Peterson Institute, he rushed out a
paper co-authored by Professor Myra McClure that claimed
effectively to negate the WPI findings.
In the same series of correspondence,
Wessely states on the record:
“At the time of writing I can
say with my hand on my heart that I believe that the treatments
that we recommend and use in our clinic are currently the best
there is – and nothing i have seen, or read about, suggests
otherwise”. |
Retroviral involvement in ME/CFS
notwithstanding, might this be taken to indicate what the PACE
Trial results will conclude?
This firm statement from Professor
Wessely (ie. that nothing he has seen or read suggests other
than that his favoured behavioural interventions are the best
treatment for ME/CFS) seems to indicate that, as noted by the
person from Australia who posted the very revealing exchange of
correspondence, Wessely’s comments are a classic case of the
Semmelweis reflex, defined as “the tendency to reject new
evidence that contradicts an established paradigm”, and s/he
commented about Wessely’s stance:
“Science works by
new evidence replacing existing paradigms.
When this new evidence is presented, it is a fallacy
to reject it with the argument that it interferes
with an existing paradigm…if all scientists used
Wessely’s logic …then there would be no new
scientific discoveries”. |
Wessely maintains that the XMRV research
fails to model the role that childhood abuse, psychological
factors and other infections may play in the illness, whilst
also confirming that for the last 21 years he has promoted his
own theory that the “cognitive behavioural model” is a better
explanatory model for chronic ME/CFS than the chronic viral
paradigm that dominated at that time (and which many
believe he was instrumental in suppressing).
That patients with ME/CFS have been left
with no alternative but to suffer from on-going viral illness
for the last 21 years and have been deprived of essential
financial support because of the dominant influence of certain
psychiatrists is deplorable and may be recorded in future annals
of medicine with abhorrence and disbelief.
A recent internet post by “XMRV Global
Action” announcing that Francis Collins, Director of the US
National Institutes of Health (who oversees an annual budget of
more than $31 billion) is to open the First International
XMRV/MLV Conference on 7th September 2010 noted that
this means the NIH are taking XMRV/MLV very seriously indeed,
and that there is an element of potential scandal, given that
people with ME/CFS have been complaining of profound viral
symptoms for decades (and dropping dead from viral
cardiomyopathies and rare lymphomas) while being derided as
hypochondriacs (
http://www.facebook.com/home.php#!/pages/XMRV-Global-Action/216740433250?ref=ts
).
Yet more evidence has emerged in the UK
that the Wessely School’s various attempts to neutralise what
they may consider to be inconvenient findings simply do not
withstand logical analysis and their contemptuous dismissal of
the biomedical research will no longer carry any weight, because
their “cognitive behavioural model” has been dealt what may be a
fatal blow.
Whilst there are no children involved in
the PACE Trial, paediatrician Dr Esther Crawley is about to
start a study looking at the effect of the Lightning Process on
children aged from 8 to 18 to see if sufferers can be trained to
think differently about how ill they feel and so increase their
exercise levels, but an article in the current issue of the
American Medical Associations’ journal “Archives of Paediatrics
and Adolescent Medicine” 2010:164(9):817-823 (Biochemical and
Vascular Aspects of Paediatric Chronic Fatigue Syndrome/Myalgic
Encephalomyelitis; G. Kennedy et al:) shows how unsuitable such
a study may be.
There are thought to be about 15,000
children in the UK with ME/CFS and a team from Dundee that was
funded by ME Research UK and The Young ME Sufferers Trust has found abnormalities in the blood of all the
children with ME/CFS tested but not in controls, the results
being similar to those previously found in adults with ME/CFS
and consistent with an activated inflammatory process.
Professor Jill Belch from the Vascular
and Inflammatory Diseases Research Unit, Ninewells Hospital and
Medical School, Dundee, explained this new research on the BBC
Radio 4 Today programme on 7th September 2010, saying
that they have demonstrated two important findings, the first
being an abnormal level of an inflammatory chemical in the blood
and that this is matched by abnormal white blood cell behaviour;
she explained that this is important because “finding an
abnormality is halfway to finding a treatment”. The second
finding, said Professor Belch, is that ME/CFS is a
physical abnormality, and this is important because
“there
has been some question in some peoples’ mind whether this
disease might actually be a disease of the mind, and I think
finding an abnormality reassures us that this is a genuine
physical illness”. The interviewer (Sarah Montague)
responded by asking “Because so many have questioned whether
ME even exists?”, to which Professor Belch replied: “That’s
absolutely right”. Professor Belch went on to say: “These
children have a terribly damaged lifestyle, and if you add
disbelief on to that, the parents don’t know whether to believe
the child, (and) the doctors don’t know”. Sarah
Montague summarised the findings, saying: “What you’ve found
is what happens to a body that’s reacting to a virus?”, to
which Professor Belch replied: “That’s correct”, adding:
“There is no doubt that once you have an abnormality to
target, treatments can follow”
http://news.bbc.co.uk/today/hi/today/newsid_8975000/8975412.stm
|
Commenting on the Dundee research, Dr
Neil Abbot, Director of Operations at MERUK, said: “The study
undoubtedly adds greater scientific weight to the existence of a
condition which, sadly, many still fail to acknowledge in spite
of its severity” (
http://www.bbc.co.uk/news/uk-scotland-tayside-central-11204884
).
The importance of this study cannot be
over-emphasised because of the potential long-term consequences
for cardiovascular disease and because, as Dr Abbot points out,
the white blood cells are releasing an excessive amount of
highly reactive free radicals, possibly from exercising muscle
(which would contra-indicate incremental aerobic exercise) and
the white blood cells provide evidence of “a persistent or
reactivating viral infection triggering apoptosis of white blood
cells”.
Many people around the world believe that
the Wessely School’s “cognitive behavioural model” of ME/CFS
(which includes the use of incremental aerobic exercise) has
been built on sand, not science. Wessely’s own recent comments,
together with the now irrefutable evidence of viral involvement
in ME/CFS, can only have assisted the cognitive behavioural
model’s (long overdue) disappearance from the discipline of
medicine.
It may be coincidence, but a video is
currently circulating on the internet featuring Francis Collins,
Director of the NIH, singing “The Times They Are A-Changin’ “ on
Capitol Hill (Rock Stars of Science:
http://www.youtube.com/watch?v=2SNHDlKYSt0&forumid=331851 ).
The times are indeed changing for those
with ME/CFS because the stranglehold of the Wessely School has
finally been severed but they will, naturally, go down fighting
because their professional careers in relation to ME/CFS have
been shown to be scientifically invalid, a record of which
no-one could be proud.